Indolent non-Hodgkin lymphomas (NHLs) is a very slow growing asymptomatic cancer that often get diagnosed at a very late stage. In many cases, it cannot be treated with radiation therapy as all the lymphoma cannot be included in the radiation field. Single drugs may be used, but a combination of chemotherapy is mostly used along with biologic therapy. Indolent NHLs are widely subjected to Biological therapy along with chemotherapy.
Rituximab (Rituxan) is the biological therapy used most often. It is only used for B-cell lymphomas. However, the prognosis and outcome of NHL patients who are refractory to rituximab treatment are very poor. This research publication deals with investigating the role of combination of obinutuzumab (GA101), a novel glyco-engineered type II anti-CD20 monoclonal antibody and bendamustine, a nitrogen mustard over bendamustine monotherapy in treating rituximab…
